Syncom Formulations (India) Limited

BSE: 524470
Syncom Formulations (India) Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials and compliance.
CIN L24239MH1988PLC047759 Incorporated 21 June 1988 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - BSE: 524470 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹489.17 Cr
▲ 5.2% YoY
Computed EBITDA · FY 2026
₹108.77 Cr
▲ 51.99% YoY
Net profit · FY 2026
₹76.44 Cr
▲ 54.62% YoY
Authorised capital
₹95 Cr
Registered with MCA
Paid-up capital
₹94 Cr
Issued & subscribed
Open charges
₹53.3 Cr
Satisfied ₹156.68 Cr
Company age
38 yrs
Est. 1988
Employees · EPFO
681
Latest available

About Syncom Formulations (India) Limited

Data last updated: 14 July 2026

Syncom Formulations (India) Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 21 June 1988, the company has been in operation for over 38 years.

Registered with ROC Mumbai under CIN L24239MH1988PLC047759. Listed on BSE: 524470.

Capital: an authorised share capital of ₹95 Cr and a paid-up capital of ₹94 Cr. Formerly known as Syncom Formulations (India) Pvt Limited. It is led by directors including Vijay Shankarlal Bankda and Kedarmal Shankarlal Bankda.

Last AGM: 29 September 2025. Financial statements filed for year ended 31 March 2025. Office: 7 Niraj Industrial Estate Off Mahakali Caves Road Andheri (East), Mumbai, Maharashtra, India – 400093.

As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹489.17 Cr, a growth of 5.2% compared to the previous year. The net worth stands at ₹414.99 Cr (up 21.29% YoY). Total assets are valued at ₹533.85 Cr (up 29.17% YoY).

The company has a workforce of approximately 681 employees as per the latest available data. Its group structure includes 3 subsidiaries.

The company is associated with 1 brand - Syncom Formulations. As per MCA filings, the company has open charges of ₹53.3 Cr and satisfied charges of ₹156.68 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sfil.in.

Company Details of Syncom Formulations (India) Limited
CIN L24239MH1988PLC047759
Registration Number 047759
Incorporation Date 21 June 1988
ROC Mumbai
Listing Status Listed (BSE: 524470)
Company Status Active
Date of Last AGM 29 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Vijay Shankarlal Bankda Managing Director Kedarmal Shankarlal Bankda Whole-Time Director Ankit Kedarmal Bankda Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    sfil.in
  • Social Media
    Locked
  • Registered Address
    7 Niraj Industrial Estate Off Mahakali Caves Road Andheri (East), Mumbai, Maharashtra, India – 400093
  • Industry
    Pharma, Drug Formulation & Development
Company report
Syncom Formulations (India) Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Syncom Formulations (India) Limited report

Financials, compliance, directors, charges, ownership and filings for Syncom Formulations (India) Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has one previous CIN (Corporate Identification Number): U24239MH1988PLC047759. The current CIN is L24239MH1988PLC047759, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24239MH1988PLC047759 Current
U24239MH1988PLC047759 Previous

Associated Brands with Syncom Formulations (India) Limited

Syncom Formulations (India) Limited operates one associated brand: Syncom Formulations. These brands represent Syncom Formulations (India) Limited's diversified market presence and brand portfolio.

Brand Description Website
Syncom Formulations
Pharmaceutical formulations are manufactured and exported in various dosage forms. syncomformulations.com

Business Activity of Syncom Formulations (India) Limited

Syncom Formulations (India) Limited is engaged in principal business activities including manufacturing and trade, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products, wholesale trading. The company has 2 registered principal business activity segments, demonstrating its operational diversity and market reach.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
G Trade G1 Wholesale Trading Locked
Premium access

Business activity turnover details for Syncom Formulations (India) Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Syncom Formulations (India) Limited

Syncom Formulations (India) Limited is audited by Sanjay Mehta And Associates, Chartered Accountants (ICAI peer reviewed, certificate valid till 2027-03-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Sanjay Mehta And Associates, Chartered Accountants (ICAI peer reviewed, certificate valid till 2027-03-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Syncom Formulations (India) Limited

Syncom Formulations (India) Limited is currently managed by 6 directors, with 14 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Vijay Shankarlal Bankda
Also directs: Syncom Formulations (India) Limited, Sante Biotech Private Limited, Synmex Pharma Private Limited and 1 more
Managing Director 01 Dec 1999 26 Years 8 Months Current
Kedarmal Shankarlal Bankda
Also directs: Syncom Formulations (India) Limited, Sante Biotech Private Limited, Synmex Pharma Private Limited and 1 more
Whole-Time Director 13 Apr 1992 34 Years 4 Months Current
Ankit Kedarmal Bankda
Also directs: Syncom Formulations (India) Limited, Ruj Infotech Llp, Strand Developers Private Limited
Whole-Time Director 09 Aug 2025 1 Years 0 Months Current
Ruchi Jindal
Also directs: Syncom Formulations (India) Limited
Director 28 Jun 2022 4 Years 1 Months Current
Ankit Jain
Also directs: Syncom Formulations (India) Limited
Director 14 Aug 2023 3 Years 0 Months Current
Ritesh Kumar Lunkad
Also directs: Syncom Formulations (India) Limited
Director 14 Aug 2023 3 Years 0 Months Current
View all directors

Financials of Syncom Formulations (India) Limited FY 2026 filings available

Syncom Formulations (India) Limited reported revenue of ₹489.17 Cr (up 5.2% YoY) for FY 2026.

Revenue · FY 2026
₹489.17 Cr ▲ 5.2%
Profit · FY 2026
₹76.44 Cr ▲ 54.62%
Computed EBITDA · FY 2026
₹108.77 Cr ▲ 51.99%
Revenue₹ Cr · Consolidated0200400600FY 2023: ₹224 Cr224FY 2023FY 2024: ₹263 Cr · +17.5% YoY263+17.5%FY 2024FY 2025: ₹465 Cr · +76.6% YoY465+76.6%FY 2025FY 2026: ₹489 Cr · +5.2% YoY489+5.2%FY 2026
Net Profit₹ Cr · Consolidated050100FY 2023: ₹20 Cr20.1FY 2023FY 2024: ₹25 Cr · +26.1% YoY25.3+26.1%FY 2024FY 2025: ₹49 Cr · +95.3% YoY49.4+95.3%FY 2025FY 2026: ₹76 Cr · +54.6% YoY76.4+54.6%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year050100150Q1'25: ₹87 Cr · +45.8% YoY87.3+45.8%Q1'25Q2'25: ₹102 Cr · +60.3% YoY102+60.3%Q2'25Q3'25: ₹128 Cr · +95.8% YoY128+95.8%Q3'25Q4'25: ₹149 Cr · +99.6% YoY149+99.6%Q4'25Q1'26: ₹117 Cr · +34% YoY117+34%Q1'26Q2'26: ₹122 Cr · +19% YoY122+19%Q2'26Q3'26: ₹115 Cr · -9.7% YoY115-9.7%Q3'26Q4'26: ₹135 Cr · -9% YoY135-9%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Revenue from Operations ₹489.17 Cr ₹465.01 Cr ₹263.39 Cr ₹224.25 Cr
Other Income ₹31.34 Cr ₹17.43 Cr ₹13.53 Cr ₹14.6 Cr
Total Income ₹520.51 Cr ₹482.45 Cr ₹276.91 Cr ₹238.85 Cr
Cost of Materials Consumed ₹220.94 Cr ₹278.03 Cr ₹131.53 Cr ₹99.46 Cr
Purchases of Stock-in-Trade ₹67.23 Cr ₹39.97 Cr ₹27.11 Cr ₹42.61 Cr
Changes in Inventories -₹3.89 Cr -₹10.66 Cr -₹1.75 Cr -₹37.61 Lakh
Employee Benefit Expense ₹67.09 Cr ₹52.17 Cr ₹35.06 Cr ₹25.87 Cr
Finance Costs ₹1.16 Cr ₹86.49 Lakh ₹4.47 Cr ₹3.13 Cr
Depreciation & Amortisation ₹6.53 Cr ₹5.19 Cr ₹4.72 Cr ₹4.54 Cr
Other Expenses ₹60.38 Cr ₹51.37 Cr ₹41.8 Cr ₹37.06 Cr
Total Expenses ₹419.43 Cr ₹416.94 Cr ₹242.94 Cr ₹212.29 Cr
Profit Before Exceptional Items & Tax ₹101.08 Cr ₹65.51 Cr ₹33.98 Cr ₹26.56 Cr
Exceptional Items ₹3.69 Lakh ₹58,000 -₹2.39 Lakh ₹1.33 Lakh
Profit Before Tax ₹101.12 Cr ₹65.51 Cr ₹33.95 Cr ₹26.57 Cr
Total Tax Expense ₹24.68 Cr ₹16.08 Cr ₹8.64 Cr ₹6.5 Cr
Net Profit ₹76.44 Cr ₹49.43 Cr ₹25.31 Cr ₹20.07 Cr
  attributable to Owners ₹0 ₹0 - ₹0
  attributable to NCI ₹0 ₹0 - ₹0
Other Comprehensive Income -₹3.61 Cr ₹4.58 Cr ₹6.81 Cr ₹1.96 Cr
Total Comprehensive Income ₹72.83 Cr ₹54.01 Cr ₹32.13 Cr ₹22.03 Cr
EBITDA (computed) ₹108.77 Cr ₹71.57 Cr ₹43.17 Cr ₹34.23 Cr
Basic EPS ₹0.81 ₹0.57 ₹0.34 ₹0.24
Diluted EPS ₹0.81 ₹0.57 ₹0.34 ₹0.24
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹533.85 Cr ₹413.28 Cr ₹404.66 Cr ₹377.83 Cr
Non-current Assets ₹203.48 Cr ₹143.31 Cr ₹129.88 Cr ₹196.14 Cr
Current Assets ₹330.37 Cr ₹269.97 Cr ₹274.78 Cr ₹181.69 Cr
Property, Plant & Equipment ₹89.77 Cr ₹77.53 Cr ₹72.31 Cr ₹43.22 Cr
Inventories ₹62.88 Cr ₹41.33 Cr ₹21.08 Cr ₹21.2 Cr
Trade Receivables ₹110.5 Cr ₹107.55 Cr ₹103.3 Cr ₹75.51 Cr
Cash & Equivalents ₹5.15 Cr ₹71.2 Lakh ₹63.38 Cr ₹87.97 Lakh
Equity (Net Worth) ₹414.99 Cr ₹342.16 Cr ₹288.14 Cr ₹256.01 Cr
Equity Share Capital ₹94 Cr ₹94 Cr ₹94 Cr ₹94 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹1.47 Cr ₹4.58 Cr ₹72.49 Cr ₹83.18 Cr
Total Debt (computed) ₹1.47 Cr ₹4.58 Cr ₹72.49 Cr ₹83.18 Cr
Current Liabilities ₹103.73 Cr ₹59.31 Cr ₹106.52 Cr ₹113.16 Cr
Total Liabilities ₹118.86 Cr ₹71.12 Cr ₹116.52 Cr ₹121.82 Cr
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Operating Cash Flow ₹58.08 Cr ₹23.44 Cr -₹5.96 Cr ₹10.53 Cr
Investing Cash Flow -₹50.62 Cr -₹18.2 Cr ₹83.02 Cr -₹44.95 Cr
Financing Cash Flow -₹3.02 Cr -₹67.9 Cr -₹14.56 Cr ₹35 Cr
Capital Expenditure ₹11.67 Cr ₹9.96 Cr ₹8.14 Cr ₹20.63 Cr
Free Cash Flow (computed) ₹46.41 Cr ₹13.48 Cr -₹14.09 Cr -₹10.11 Cr
Dividends Paid ₹0 ₹0 ₹0 ₹2.82 Cr
Net Change in Cash ₹4.44 Cr -₹62.67 Cr ₹62.5 Cr ₹57.8 Lakh
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹135.41 Cr ₹115.14 Cr ₹121.72 Cr ₹116.9 Cr ₹148.88 Cr ₹127.53 Cr ₹102.31 Cr ₹87.26 Cr ₹74.57 Cr ₹65.14 Cr ₹63.84 Cr ₹59.84 Cr
Other Income ₹14.55 Cr ₹5.5 Cr ₹5.25 Cr ₹6.03 Cr ₹6.94 Cr ₹4.04 Cr ₹4.15 Cr ₹1.34 Cr ₹3.1 Cr ₹4.56 Cr ₹4 Cr ₹1.87 Cr
Total Income ₹149.97 Cr ₹120.64 Cr ₹126.97 Cr ₹122.94 Cr ₹155.82 Cr ₹131.57 Cr ₹106.46 Cr ₹88.59 Cr ₹77.67 Cr ₹69.69 Cr ₹67.84 Cr ₹61.71 Cr
Cost of Materials Consumed ₹67.45 Cr ₹47.45 Cr ₹46.43 Cr ₹59.61 Cr ₹80.16 Cr ₹76.26 Cr ₹68.58 Cr ₹53.03 Cr ₹37.88 Cr ₹37.75 Cr ₹33.25 Cr ₹22.65 Cr
Purchases of Stock-in-Trade ₹20.55 Cr ₹15.71 Cr ₹15.29 Cr ₹15.68 Cr ₹15.79 Cr ₹7.23 Cr ₹12.66 Cr ₹4.29 Cr ₹5.02 Cr ₹4.5 Cr ₹8.37 Cr ₹9.21 Cr
Changes in Inventories -₹4.68 Cr -₹2.12 Cr ₹9.04 Cr -₹6.12 Cr ₹4.41 Cr ₹3.17 Cr -₹15.44 Cr -₹2.8 Cr -₹20.04 Lakh -₹2.72 Cr -₹2.52 Cr ₹3.68 Cr
Employee Benefit Expense ₹16.95 Cr ₹17.45 Cr ₹16.73 Cr ₹15.95 Cr ₹14.97 Cr ₹13.95 Cr ₹12.4 Cr ₹9.65 Cr ₹8.69 Cr ₹9.74 Cr ₹9 Cr ₹7.63 Cr
Finance Costs ₹37.59 Lakh ₹26.34 Lakh ₹26.49 Lakh ₹25.08 Lakh ₹11.68 Lakh ₹19.82 Lakh ₹15.96 Lakh ₹39.03 Lakh ₹1.2 Cr ₹1.08 Cr ₹1.08 Cr ₹1.12 Cr
Depreciation & Amortisation ₹2.48 Cr ₹1.36 Cr ₹1.35 Cr ₹1.34 Cr ₹1.29 Cr ₹1.31 Cr ₹1.3 Cr ₹1.3 Cr ₹1.3 Cr ₹1.45 Cr ₹87.88 Lakh ₹1.1 Cr
Other Expenses ₹13.14 Cr ₹15.44 Cr ₹15.83 Cr ₹15.97 Cr ₹15.78 Cr ₹12.2 Cr ₹11.95 Cr ₹12.64 Cr ₹13.76 Cr ₹8.52 Cr ₹9.33 Cr ₹10.2 Cr
Total Expenses ₹116.26 Cr ₹95.55 Cr ₹104.93 Cr ₹102.69 Cr ₹132.53 Cr ₹114.31 Cr ₹91.61 Cr ₹78.49 Cr ₹67.64 Cr ₹60.31 Cr ₹59.39 Cr ₹55.6 Cr
Profit Before Exceptional Items & Tax ₹33.71 Cr ₹25.09 Cr ₹22.04 Cr ₹20.25 Cr ₹23.29 Cr ₹17.26 Cr ₹14.85 Cr ₹10.1 Cr ₹10.03 Cr ₹9.39 Cr ₹8.45 Cr ₹6.11 Cr
Exceptional Items -₹44,000 ₹0 ₹0 ₹4.13 Lakh ₹82,000 ₹0 ₹0 ₹0 ₹0 -₹2.39 Lakh ₹0 ₹0
Profit Before Tax ₹33.7 Cr ₹25.09 Cr ₹22.04 Cr ₹20.29 Cr ₹23.3 Cr ₹17.26 Cr ₹14.85 Cr ₹10.1 Cr ₹10.03 Cr ₹9.36 Cr ₹8.45 Cr ₹6.11 Cr
Total Tax Expense ₹8.53 Cr ₹6.18 Cr ₹5.44 Cr ₹4.54 Cr ₹5.61 Cr ₹4.26 Cr ₹3.74 Cr ₹2.47 Cr ₹2.63 Cr ₹2.36 Cr ₹1.94 Cr ₹1.72 Cr
Net Profit ₹25.17 Cr ₹18.91 Cr ₹16.6 Cr ₹15.75 Cr ₹17.69 Cr ₹13 Cr ₹11.11 Cr ₹7.63 Cr ₹7.4 Cr ₹7 Cr ₹6.51 Cr ₹4.4 Cr
  attributable to Owners ₹0 ₹0 ₹0 - ₹0 ₹0 - ₹0 - ₹0 ₹0 -
  attributable to NCI ₹0 ₹0 ₹0 - ₹0 ₹0 - ₹0 - ₹0 ₹0 -
Other Comprehensive Income -₹9.95 Cr ₹2.36 Cr -₹5.58 Lakh ₹4.04 Cr -₹2.28 Cr ₹18.4 Lakh ₹3.92 Cr ₹2.76 Cr ₹1.65 Cr ₹1.86 Cr ₹1.24 Cr ₹2.07 Cr
Total Comprehensive Income ₹15.22 Cr ₹21.27 Cr ₹16.55 Cr ₹19.79 Cr ₹15.41 Cr ₹13.19 Cr ₹15.03 Cr ₹10.39 Cr ₹9.05 Cr ₹8.86 Cr ₹7.76 Cr ₹6.46 Cr
EBITDA (computed) ₹36.57 Cr ₹26.71 Cr ₹23.65 Cr ₹21.84 Cr ₹24.7 Cr ₹18.77 Cr ₹16.31 Cr ₹11.79 Cr ₹12.52 Cr ₹11.91 Cr ₹10.4 Cr ₹8.33 Cr
Basic EPS ₹0.27 ₹0.23 ₹0.18 ₹0.21 ₹0.16 ₹0.14 ₹0.16 ₹0.11 ₹0.10 ₹0.09 ₹0.08 ₹0.07
Diluted EPS ₹0.27 ₹0.23 ₹0.18 ₹0.21 ₹0.16 ₹0.14 ₹0.16 ₹0.11 ₹0.10 ₹0.09 ₹0.08 ₹0.07
Latest 12 quarters shown.
Segment · Q4 FY26 (latest quarter) Revenue Result (PBIT) Assets Liabilities
Pharmaceuticals Drugs & Formulations ₹149 Cr ₹33.72 Cr ₹439.76 Cr ₹117.14 Cr
Trading of Commodities ₹4.03 Lakh -₹4.35 Lakh ₹66.51 Lakh ₹4.12 Lakh
Renting of Property ₹92.04 Lakh ₹40.54 Lakh ₹93.42 Cr ₹1.68 Cr
Segment · FY 2026 (annual) Revenue Result (PBIT) Assets Liabilities
Pharmaceuticals Drugs & Formulations ₹515.73 Cr ₹99.32 Cr - -
Trading of Commodities ₹1.1 Cr -₹2.63 Lakh - -
Renting of Property ₹3.68 Cr ₹2.98 Cr - -
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Revenue from Operations ₹486.57 Cr ₹462.85 Cr ₹258.36 Cr ₹224.64 Cr
Other Income ₹30.97 Cr ₹17.19 Cr ₹13.1 Cr ₹14.61 Cr
Total Income ₹517.54 Cr ₹480.04 Cr ₹271.46 Cr ₹239.25 Cr
Cost of Materials Consumed ₹220.94 Cr ₹278.03 Cr ₹131.53 Cr ₹99.46 Cr
Purchases of Stock-in-Trade ₹66.7 Cr ₹39.48 Cr ₹26.21 Cr ₹42.61 Cr
Changes in Inventories -₹3.9 Cr -₹10.62 Cr -₹2.18 Cr ₹5.03 Lakh
Employee Benefit Expense ₹67.09 Cr ₹52.17 Cr ₹35.06 Cr ₹25.87 Cr
Finance Costs ₹1.1 Cr ₹85.02 Lakh ₹4.45 Cr ₹3.13 Cr
Depreciation & Amortisation ₹6.53 Cr ₹5.19 Cr ₹4.72 Cr ₹4.54 Cr
Other Expenses ₹58.59 Cr ₹50.29 Cr ₹39.89 Cr ₹37.04 Cr
Total Expenses ₹417.05 Cr ₹415.39 Cr ₹239.68 Cr ₹212.7 Cr
Profit Before Exceptional Items & Tax ₹100.49 Cr ₹64.65 Cr ₹31.78 Cr ₹26.55 Cr
Exceptional Items ₹3.69 Lakh ₹58,000 -₹2.39 Lakh ₹1.33 Lakh
Profit Before Tax ₹100.53 Cr ₹64.66 Cr ₹31.76 Cr ₹26.57 Cr
Total Tax Expense ₹24.52 Cr ₹15.79 Cr ₹8.14 Cr ₹6.5 Cr
Net Profit ₹76.01 Cr ₹48.87 Cr ₹23.62 Cr ₹20.07 Cr
Other Comprehensive Income -₹3.61 Cr ₹4.58 Cr ₹6.81 Cr ₹1.96 Cr
Total Comprehensive Income ₹72.4 Cr ₹53.45 Cr ₹30.44 Cr ₹22.03 Cr
EBITDA (computed) ₹108.13 Cr ₹70.7 Cr ₹40.95 Cr ₹34.22 Cr
Basic EPS ₹0.81 ₹0.57 ₹0.32 ₹0.24
Diluted EPS ₹0.81 ₹0.57 ₹0.32 ₹0.24
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹529.26 Cr ₹409.69 Cr ₹391.5 Cr ₹376.94 Cr
Non-current Assets ₹203.23 Cr ₹142.22 Cr ₹128.86 Cr ₹196.17 Cr
Current Assets ₹326.03 Cr ₹267.46 Cr ₹262.64 Cr ₹180.77 Cr
Property, Plant & Equipment ₹89.77 Cr ₹77.53 Cr ₹72.31 Cr ₹43.22 Cr
Inventories ₹62.85 Cr ₹41.29 Cr ₹21.08 Cr ₹20.77 Cr
Trade Receivables ₹107.6 Cr ₹106.94 Cr ₹93.21 Cr ₹75.14 Cr
Cash & Equivalents ₹5.12 Cr ₹69.23 Lakh ₹63.35 Cr ₹82.7 Lakh
Equity (Net Worth) ₹412.3 Cr ₹339.9 Cr ₹286.45 Cr ₹256.01 Cr
Equity Share Capital ₹94 Cr ₹94 Cr ₹94 Cr ₹94 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹68.13 Lakh ₹4.04 Cr ₹71.65 Cr ₹83.18 Cr
Total Debt (computed) ₹68.13 Lakh ₹4.04 Cr ₹71.65 Cr ₹83.18 Cr
Current Liabilities ₹101.83 Cr ₹57.97 Cr ₹95.05 Cr ₹112.27 Cr
Total Liabilities ₹116.96 Cr ₹69.78 Cr ₹105.05 Cr ₹120.93 Cr
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Operating Cash Flow ₹58.29 Cr ₹23.31 Cr -₹5.94 Cr ₹10.5 Cr
Investing Cash Flow -₹50.64 Cr -₹18.38 Cr ₹83.83 Cr -₹44.97 Cr
Financing Cash Flow -₹3.22 Cr -₹67.59 Cr -₹15.37 Cr ₹35 Cr
Capital Expenditure ₹11.67 Cr ₹9.96 Cr ₹8.14 Cr ₹20.63 Cr
Free Cash Flow (computed) ₹46.62 Cr ₹13.35 Cr -₹14.07 Cr -₹10.14 Cr
Dividends Paid ₹0 ₹0 ₹0 ₹2.82 Cr
Net Change in Cash ₹4.43 Cr -₹62.66 Cr ₹62.52 Cr ₹52.53 Lakh
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹134 Cr ₹114.59 Cr ₹121.44 Cr ₹116.55 Cr ₹148.46 Cr ₹127.03 Cr ₹101.49 Cr ₹86.83 Cr ₹73.27 Cr ₹63.34 Cr ₹62.39 Cr ₹59.36 Cr
Other Income ₹14.23 Cr ₹5.48 Cr ₹5.23 Cr ₹6.02 Cr ₹6.9 Cr ₹3.82 Cr ₹4.18 Cr ₹1.31 Cr ₹2.87 Cr ₹4.35 Cr ₹4 Cr ₹1.88 Cr
Total Income ₹148.23 Cr ₹120.07 Cr ₹126.67 Cr ₹122.57 Cr ₹155.37 Cr ₹130.85 Cr ₹105.68 Cr ₹88.14 Cr ₹76.14 Cr ₹67.69 Cr ₹66.39 Cr ₹61.24 Cr
Cost of Materials Consumed ₹67.45 Cr ₹47.45 Cr ₹46.43 Cr ₹59.61 Cr ₹80.16 Cr ₹76.26 Cr ₹68.58 Cr ₹53.03 Cr ₹37.88 Cr ₹37.75 Cr ₹33.25 Cr ₹22.65 Cr
Purchases of Stock-in-Trade ₹20.15 Cr ₹15.57 Cr ₹15.35 Cr ₹15.62 Cr ₹15.68 Cr ₹7.13 Cr ₹12.6 Cr ₹4.06 Cr ₹4.89 Cr ₹3.98 Cr ₹8.2 Cr ₹9.14 Cr
Changes in Inventories -₹4.65 Cr -₹2.18 Cr ₹9.09 Cr -₹6.16 Cr ₹4.39 Cr ₹3.23 Cr -₹15.61 Cr -₹2.63 Cr -₹20.04 Lakh -₹2.8 Cr -₹3.09 Cr ₹3.91 Cr
Employee Benefit Expense ₹16.95 Cr ₹17.45 Cr ₹16.73 Cr ₹15.95 Cr ₹14.97 Cr ₹13.95 Cr ₹12.4 Cr ₹9.65 Cr ₹8.69 Cr ₹9.74 Cr ₹9 Cr ₹7.63 Cr
Finance Costs ₹36.71 Lakh ₹25 Lakh ₹25.03 Lakh ₹23.74 Lakh ₹8.92 Lakh ₹21.23 Lakh ₹16.22 Lakh ₹38.65 Lakh ₹1.17 Cr ₹1.08 Cr ₹1.08 Cr ₹1.12 Cr
Depreciation & Amortisation ₹2.48 Cr ₹1.36 Cr ₹1.35 Cr ₹1.34 Cr ₹1.29 Cr ₹1.31 Cr ₹1.3 Cr ₹1.3 Cr ₹1.3 Cr ₹1.45 Cr ₹87.88 Lakh ₹1.1 Cr
Other Expenses ₹12.62 Cr ₹15.12 Cr ₹15.11 Cr ₹15.75 Cr ₹15.78 Cr ₹11.86 Cr ₹11.59 Cr ₹12.25 Cr ₹13.2 Cr ₹7.88 Cr ₹8.93 Cr ₹9.88 Cr
Total Expenses ₹115.36 Cr ₹95.03 Cr ₹104.31 Cr ₹102.35 Cr ₹132.37 Cr ₹113.95 Cr ₹91.02 Cr ₹78.05 Cr ₹66.93 Cr ₹59.07 Cr ₹58.25 Cr ₹55.43 Cr
Profit Before Exceptional Items & Tax ₹32.87 Cr ₹25.05 Cr ₹22.36 Cr ₹20.22 Cr ₹23 Cr ₹16.9 Cr ₹14.65 Cr ₹10.1 Cr ₹9.21 Cr ₹8.62 Cr ₹8.14 Cr ₹5.81 Cr
Exceptional Items -₹44,000 ₹0 ₹0 ₹4.13 Lakh ₹82,000 ₹0 -₹24,000 ₹0 ₹0 -₹2.39 Lakh ₹0 ₹0
Profit Before Tax ₹32.86 Cr ₹25.05 Cr ₹22.36 Cr ₹20.26 Cr ₹23.01 Cr ₹16.9 Cr ₹14.65 Cr ₹10.1 Cr ₹9.21 Cr ₹8.6 Cr ₹8.14 Cr ₹5.81 Cr
Total Tax Expense ₹8.29 Cr ₹6.18 Cr ₹5.52 Cr ₹4.53 Cr ₹5.51 Cr ₹4.11 Cr ₹3.7 Cr ₹2.47 Cr ₹2.46 Cr ₹2.18 Cr ₹1.94 Cr ₹1.56 Cr
Net Profit ₹24.57 Cr ₹18.86 Cr ₹16.84 Cr ₹15.73 Cr ₹17.5 Cr ₹12.79 Cr ₹10.95 Cr ₹7.63 Cr ₹6.75 Cr ₹6.42 Cr ₹6.21 Cr ₹4.25 Cr
Other Comprehensive Income -₹9.95 Cr ₹2.36 Cr -₹5.58 Lakh ₹4.04 Cr -₹2.28 Cr ₹18.4 Lakh ₹3.92 Cr ₹2.76 Cr ₹1.65 Cr ₹1.86 Cr ₹1.24 Cr ₹2.07 Cr
Total Comprehensive Income ₹14.62 Cr ₹21.23 Cr ₹16.79 Cr ₹19.77 Cr ₹15.22 Cr ₹12.98 Cr ₹14.87 Cr ₹10.39 Cr ₹8.39 Cr ₹8.28 Cr ₹7.45 Cr ₹6.32 Cr
EBITDA (computed) ₹35.71 Cr ₹26.66 Cr ₹23.96 Cr ₹21.79 Cr ₹24.38 Cr ₹18.42 Cr ₹16.11 Cr ₹11.78 Cr ₹11.68 Cr ₹11.15 Cr ₹10.1 Cr ₹8.04 Cr
Basic EPS ₹0.26 ₹0.23 ₹0.18 ₹0.21 ₹0.16 ₹0.14 ₹0.16 ₹0.11 ₹0.09 ₹0.09 ₹0.08 ₹0.07
Diluted EPS ₹0.26 ₹0.23 ₹0.18 ₹0.21 ₹0.16 ₹0.14 ₹0.16 ₹0.11 ₹0.09 ₹0.09 ₹0.08 ₹0.07
Latest 12 quarters shown.
Segment · Q4 FY26 (latest quarter) Revenue Result (PBIT) Assets Liabilities
Pharmaceuticals Drugs & Formulations ₹147.26 Cr ₹32.86 Cr ₹435.18 Cr ₹115.23 Cr
Trading of Commodities ₹4.03 Lakh -₹4.35 Lakh ₹66.51 Lakh ₹4.12 Lakh
Renting of Property ₹92.49 Lakh ₹40.99 Lakh ₹93.42 Cr ₹1.68 Cr
Segment · FY 2026 (annual) Revenue Result (PBIT) Assets Liabilities
Pharmaceuticals Drugs & Formulations ₹512.74 Cr ₹98.66 Cr - -
Trading of Commodities ₹1.1 Cr -₹2.63 Lakh - -
Renting of Property ₹3.7 Cr ₹3 Cr - -
Want more history and ratios?
You're viewing the latest exchange-filed financials for Syncom Formulations (India) Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Syncom Formulations (India) Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 50.57%, foreign institutional investors hold 0.21%, domestic institutional investors hold 0.00%, retail and other public shareholders hold 49.21% of Syncom Formulations (India) Limited. The company had 431,690 shareholders on record.

Promoters: 50.57%FII (Foreign Institutional): 0.21%Retail & Others: 49.21%
Mar 2026
QUARTER
50.57% Promoters
0.21% FII (Foreign Institutional)
49.21% Retail & Others
Promoter holding - history
Now 50.57% · Mar 2026High 50.57% · Nov 2022Low 50.57% · Nov 2022
49%49.8%50.5%51.3%52%Nov 2022Jun 2023Mar 2024Dec 2024Sep 2025Nov 2022: 50.57%Dec 2022: 50.57%Mar 2023: 50.57%Jun 2023: 50.57%Sep 2023: 50.57%Dec 2023: 50.57%Mar 2024: 50.57%Jun 2024: 50.57%Sep 2024: 50.57%Dec 2024: 50.57%Mar 2025: 50.57%Jun 2025: 50.57%Sep 2025: 50.57%Dec 2025: 50.57%Mar 2026: 50.57%50.57%50.57%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters50.57%50.57%50.57%50.57%50.57%50.57%
Public49.43%49.43%49.43%49.43%49.43%49.43%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023
Promoters50.57%50.57%50.57%50.57%
Public49.43%49.43%49.43%49.43%
Promoter change (YoY, %pts)+0.00+0.00+0.00-

Board & Governance of Syncom Formulations (India) Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Syncom Formulations (India) Limited has 6 directors - 3 independent and 3 executive. The board is chaired by Ankit Kedarmal Bankda.

DirectorPositionOn board sinceListed boards
Ankit Kedarmal Bankda Executive Director · Chairperson 2025-08-09 1
Kedarmal Shankarlal Bankda Executive Director 1992-04-13 1
Vijay Shankarlal Bankda Executive Director · MD 1999-12-01 1
Ruchi Jindal Non-Executive - Independent Director 2022-06-28 1
Ritesh Kumar Lunkad Non-Executive - Independent Director 2023-08-14 1
Ankit Jain Non-Executive - Independent Director 2023-08-14 1
Board Committees
CommitteeMembers
Audit Committee Ankit Jain (Chairperson), Ritesh Kumar Lunkad, Ruchi Jindal
Nomination and remuneration committee Ankit Jain (Chairperson), Ritesh Kumar Lunkad, Ruchi Jindal
Stakeholders Relationship Committee Ankit Jain (Chairperson), Ritesh Kumar Lunkad, Ruchi Jindal
Risk Management Committee Vijay Shankarlal Bankda (Chairperson), Ankit Kedarmal Bankda, Ankit Jain
Corporate Social Responsibility Committee Kedarmal Shankarlal Bankda (Chairperson), Vijay Shankarlal Bankda, Ankit Jain

Group Structure of Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has 3 subsidiary companies. This group structure data is as of FY 2024. The corporate group structure reflects Syncom Formulations (India) Limited's business expansion strategy and organizational complexity.

3
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Sante Biotech Private Limited U51909MP2022PTC061915 -
Synmex Pharma Private Limited U51909MP2022PTC061919 -
Vincit Biotech International Private Lim U51909MP2022PTC061970 -

Showing major subsidiaries. Total: 3.

Charges & Borrowings of Syncom Formulations (India) Limited

Open charges
₹53.3 Cr
Satisfied charges
₹156.68 Cr
Breakdown by lending institutions
Hdfc Bank Limited₹53.30 Cr
Latest charge details
DateLenderAmountStatus
19 Jan 2026 Hdfc Bank Limited ₹3.8 Cr Open
16 Dec 2025 Hdfc Bank Limited ₹40 Cr Open
01 Oct 2025 Hdfc Bank Limited ₹9.5 Cr Open
28 Dec 2020 Hdfc Bank Limited ₹100 Cr Satisfied
23 May 2002 Dena Bank ₹12.77 Cr Satisfied

Total charge records: 22 View all charges

Employees and EPFO Compliance at Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has a workforce of 681 employees as of Mar 27, 2025.

Employee count
681
Active EPFO establishments
2
Employee growth
-17.25%
Premium access

Employee and EPFO history for Syncom Formulations (India) Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Syncom Formulations (India) Limited

Premium access

GST registrations and filing compliance for Syncom Formulations (India) Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Syncom Formulations (India) Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Syncom Formulations (India) Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Syncom Formulations (India) Limited

Premium access

MSME payment history for Syncom Formulations (India) Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Syncom Formulations (India) Limited

Premium access

Corporate group structure for Syncom Formulations (India) Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Syncom Formulations (India) Limited

Premium access

MCA filings and documents for Syncom Formulations (India) Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Syncom Formulations (India) Limited

Charges
19 Jan 2026
A charge with Hdfc Bank Limited amounted to Rs. 3.80 Cr with Charge ID 101224854 was registered on 19 Jan 2026.
Charges
16 Dec 2025
A charge with Hdfc Bank Limited amounted to Rs. 40.00 Cr with Charge ID 101213019 was registered on 16 Dec 2025.
Charges
01 Oct 2025
A charge with Hdfc Bank Limited amounted to Rs. 9.50 Cr with Charge ID 101172185 was registered on 01 Oct 2025.
Activity
29 Sep 2025
Syncom Formulations (India) Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Directors
08 Sep 2025
Rahul Vijay Bankda was appointed as a Cfo on 08 Sep 2025 & has been associated with this company since 11 months 15 days.
Directors
09 Aug 2025
Ankit Kedarmal Bankda was appointed as a Whole-time director on 09 Aug 2025 & has been associated with this company since 1 year 14 days.

Recent News on Syncom Formulations (India) Limited

Frequently Asked Questions about Syncom Formulations (India) Limited

Syncom Formulations (India) Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 21 June 1988 (38+ years old) and is registered under CIN L24239MH1988PLC047759. Listed on BSE: 524470. The company has 681 employees.

Syncom Formulations (India) Limited reported revenue of ₹489.17 Cr for FY 2026 (up 5.2% YoY) based on consolidated NSE filings.

The current directors of Syncom Formulations (India) Limited are:

The primary industry of Syncom Formulations (India) Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Syncom Formulations (India) Limited is listed on BSE with code 524470.

Syncom Formulations (India) Limited can be reached at the registered office: 7 Niraj Industrial Estate Off Mahakali Caves Road Andheri East, Mumbai, Maharashtra, India – 400093, or through the website sfil.in.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available